Search Result

Results for "

splice

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Acyltransferase (2) ADC Cytotoxin (1) Akt (2) Aminoacyl-tRNA Synthetase (1) Androgen Receptor (5) Antibiotic (1) Apoptosis (9) Autophagy (4) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) Carbonic Anhydrase (1) CCR (2) CDK (3) Ceramidase (1) ClpP (1) DNA/RNA Synthesis (24) E1/E2/E3 Enzyme (1) EGFR (1) Glutaminase (2) Histone Methyltransferase (1) HIV (1) Huntingtin (1) iGluR (2) Integrin (2) IRE1 (3) Isotope-Labeled Compounds (2) LPL Receptor (1) MMP (3) MNK (1) Molecular Glues (2) NF-κB (2) Nucleoside Antimetabolite/Analog (1) OGT (2) P-glycoprotein (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Potassium Channel (2) PROTACs (2) Proteasome (2) Raf (1) SF3B1 (4) SRPK (1) VEGFR (1)
By Research Areas:	Cancer (39) Cardiovascular Disease (1) Endocrinology (2) Infection (3) Inflammation/Immunology (12) Metabolic Disease (2) Neurological Disease (18)
Oligonucleotides:	Antisense Oligonucleotides (8) Cap Analogs (1) Cap 0 (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16466

Spliceostatin A	SF3B1	Cancer
Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells .

HY-147149

BPN-15477	Others	Neurological Disease
BPN-15477 is a potent SMC (splicing modulator compound) that restores correct splicing of ELP1 (Elongator complex protein 1) exon 20. BPN-15477 corrects splicing of the ELP1 transcript, significantly increases the level of functional protein in vivo in all tissues, including brain. BPN-15477 can be used for frontotemporal dementia research .

HY-18509

IRE1α kinase-IN-2	IRE1	Cancer
IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC₅₀ of 0.82 μM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC₅₀=3.12 μM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines .

HY-E70372

SUMO Protease	Biochemical Assay Reagents	Others
SUMO Protease is highly specific for proteins containing small ubiquitin-like modifier (SUMO) tags. SUMO Protease can be used to regulates the proteins splicing, controlls protein structure and function in vitro .

HY-148384A

UHMCP1 dihydrochloride	Others	Cancer
UHMCP1 dihydrochloride is a potent UHM domain splicing inhibitor with a K_d value of 79 µM. UHMCP1 dihydrochloride prevents the SF3b155/U2AF ⁶⁵ interaction. UHMCP1 dihydrochloride impacts cell viability and RNA splicing .

HY-155812

Tyrosine kinase-IN-6	c-Met/HGFR	Cancer
Tyrosine kinase-IN-6 is a potent and promising *RON splice* variants** inhibitor with anti-cancer and o?antineoplastic effects .

HY-139104

Thailanstatin D	DNA/RNA Synthesis Apoptosis	Cancer
Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis .

HY-135785

OSMI-3	OGT Acyltransferase	Metabolic Disease
OSMI-3 (Compound 2b) is a potent, long-lasting, and cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-3 increases detained intron splicing in cells .

HY-139103

Thailanstatin C	DNA/RNA Synthesis	Cancer
Thailanstatin C is a pre-mRNA splicing inhibitor (IC₅₀= 6.84 μM) and antiproliferative agent from Burkholderia thailandensis MSMB43 .

HY-148384

UHMCP1	Others	Cancer
UHMCP1 is a chemical probe of U2AF homology motifs (UHM) with a K_d of 79 μM. UHMCP1 prevents the SF3b155/U2AF65 interaction, impacts RNA splicing and cell viability. UHMCP1 has potential anticancer properties .

HY-16399

Pladienolide B	Apoptosis SF3B1	Cancer
Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis .

HY-121249

Capeserod hydrochloride SL65.0155	5-HT Receptor	Neurological Disease
Capeserod hydrochloride (SL65.0155) is a 5-HT_4(e) receptor partial agonist (K_i=0.6 nM) with potent cognitive enhancing properties. Capeserod hydrochloride acts as a partial agonist in cells expressing 5-HT_4(b) and 5-HT_4(e) splice variants, stimulating cAMP production with IC₅₀ values ??of 244 and 29 nM, respectively. Capeserod hydrochloride is used in the study of memory impairment and dementia .

HY-150247

RNA splicing modulator 2	DNA/RNA Synthesis	Others
RNA splicing modulator 2 (compound 256) is a RNA splicing modulator .

HY-100236

Madrasin 4 Publications Verification DDD00107587	Others	Cancer
Madrasin (DDD00107587) is a splicing inhibitor that prevents formation of both splicing intermediates and products in vitro and interferes with one or more early steps in the pathway of spliceosome assembly. Madrasin also can inhibit pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA in cells .

HY-12248

Telaglenastat Maximum Cited Publications 70 Publications Verification CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .

HY-111520

NVS-SM2	DNA/RNA Synthesis	Neurological Disease
NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC₅₀ of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .

HY-150246

RNA splicing modulator 1	DNA/RNA Synthesis	Others
RNA splicing modulator 1 (compound 233) is a RNA splicing modulator, with an AC₅₀ value of <100 nM .

HY-150248

RNA splicing modulator 3	DNA/RNA Synthesis	Others
RNA splicing modulator 3 (compound 236) is a RNA splicing modulator, with an AC₅₀ value of <100 nM .

HY-136951

cp028	DNA/RNA Synthesis	Cancer
cp028 is a potent pre-mRNA splicing inhibitor. cp028 inhibits splicing in HeLa nuclear extract with an IC₅₀ value of 54 µM .

HY-144399

CD33 splicing modulator 1	Others	Neurological Disease
CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease .

HY-144399A

CD33 splicing modulator 1 hydrochloride	Others	Neurological Disease
CD33 splicing modulator 1 (Compound 1) hydrochloride is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 hydrochloride increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 hydrochloride has the potential for the research of neurodegenerative disease including Alzheimer's disease .

HY-N2360

Hinokiflavone 2 Publications Verification	E1/E2/E3 Enzyme Apoptosis MMP ClpP	Infection Inflammation/Immunology Cancer
Hinokiflavone is a novel modulator of pre-mRNA splicing activity extracted from plants with anti-inflammatory, anti-tumor and antiviral activities. Hinokiflavone is also a potent inhibitor for matrix metalloproteinases (MMPs). Hinokiflavone attenuates the virulence of Methicillin (HY-121544)-resistant staphylococcus aureus by inhibiting caseinolytic protease P (ClpP) with an IC₅₀ value of 34.36 mg/mL. Hinokiflavone induces apoptosis via the reactive oxygen species-mitochondria-mediated apoptotic pathway and inhibits tumor cell migration and invasion. Hinokiflavone is a SUMO protease inhibitor against sentrin-specific protease 1 (SENP1) activity .

HY-19620

Branaplam 10+ Cited Publications LMI070; NVS-SM1	DNA/RNA Synthesis Potassium Channel	Cancer
Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC₅₀ of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC₅₀ of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .

HY-19620A

Branaplam hydrochloride 10+ Cited Publications LMI070 hydrochloride; NVS-SM1 hydrochloride	DNA/RNA Synthesis Potassium Channel	Cancer
Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC₅₀ of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC₅₀ of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .

HY-P3522

REDV	Integrin	Cancer
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .

HY-101792A

RG7800 tetrahydrochloride 5 Publications Verification RO6885247 tetrahydrochloride	DNA/RNA Synthesis	Neurological Disease
RG7800 hydrochloride is an orally active SMN2 splicing modulator, with EC_1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; RG7800 hydrochloride has the potential to treat spinal muscular atrophy.

HY-148828

LSP-GR3	iGluR	Neurological Disease
LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.

HY-148828A

LSP-GR3 sodium	iGluR	Neurological Disease
LSP-GR3 sodium is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .

HY-156650

Votoplam	DNA/RNA Synthesis	Neurological Disease
Votoplam is a gene splicing modulator, used to inhibit Huntington's disease .

HY-141881

PROTAC-O4I2	PROTACs Apoptosis SF3B1	Cancer
PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC₅₀ value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells .

HY-135784

OSMI-2	OGT Acyltransferase	Metabolic Disease
OSMI-2 (Compound 1b) is a cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-2 increases detained intron splicing in cells .

HY-153421

PRMT5-IN-28	Histone Methyltransferase	Cancer
PRMT5-IN-28 (compound 36) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) enzyme. Protein arginine methylation is a common post-translational modification involved in gene transcription, mRNA splicing, DNA repair, protein cellular localization, cell fate determination and signal transduction, etc. Abnormal PRMT5 can promote cancer cell proliferation, resist apoptosis, enhance invasion and metastasis, and affect immune escape .

HY-101792

RG7800 5 Publications Verification RO6885247	DNA/RNA Synthesis	Others
RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.

HY-113821

1-Naphthyl phosphate potassium salt	Phosphatase	Others
1-Naphthyl phosphate potassium salt is a non-specific phosphatase inhibitor. 1-Naphthyl phosphate potassium salt decreases the splice-correcting effect .

HY-157261

UNC2383	Others	Others
UNC2383 is an oligonucleotide enhancing compound that can enhance effects of antisense oligonucleotides (ASOs), and splice switching oligonucleotides (SSOs) .

HY-112633

SMN-C3	DNA/RNA Synthesis	Others
SMN-C3 is an orally active *SMN2* splicing modulator and has the potential to treat spinal muscular atrophy (SMA).

HY-126076

VPC-80051 racemate	Others	Others
VPC-80051 racemate is a racemate of VPC-80051. VPC-80051 is a prototype inhibitor of the hnRNP A1 splicing factor .

HY-153736

NSC 194308	Others	Cancer
NSC 194308, a U2AF2-RNA complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations .

HY-112980

Nusinersen 1 Publications Verification	DNA/RNA Synthesis	Inflammation/Immunology
Nusinersen is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .

HY-112980A

Nusinersen sodium 1 Publications Verification	DNA/RNA Synthesis	Inflammation/Immunology
Nusinersen sodium is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .

HY-124648

SMN-C2	DNA/RNA Synthesis	Inflammation/Immunology
SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research .

HY-156103

mHTT-IN-2	Huntingtin	Neurological Disease
mHTT-IN-2 (compound 27) is a potent inhibitor (EC₅₀=0.066 μM) of mutant huntingtin (mHTT). mHTT-IN-2 reduces canonical splicing of HTT RNA exons [49-50] and is a splicing regulator of the huntingtin (HTT) gene. mHTT-IN-2 exhibits inhibitory activity in vitro and in vivo in human HD stem cells and mouse BACHD models. mHTT-IN-2 may be used in the study of branaplam-related peripheral neuropathy .

HY-134851

HIV-1 inhibitor-6 1 Publications Verification	HIV	Infection
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC₅₀s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC₅₀s ranging from 0.9 to 1.5 μM .

HY-109101

Risdiplam 5+ Cited Publications RG7916; RO7034067	DNA/RNA Synthesis	Neurological Disease
Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed *SMN2* pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-158783

SACLAC	Ceramidase Bcl-2 Family LPL Receptor Apoptosis	Neurological Disease
SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a K_i of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models .

HY-N2117

Isoginkgetin 10+ Cited Publications	MMP Akt NF-κB Proteasome Apoptosis Autophagy	Inflammation/Immunology Cancer
Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .

HY-117960

Orismilast LEO-32731	Phosphodiesterase (PDE)	Inflammation/Immunology
Orismilast (LEO-32731) is an orally active and selective PDE4 inhibitor used for the research of inflammatory diseases. Orismilast demonstrates potent inhibition of PDE4B and PDE4D subtype splice variants .

HY-148772

PTC258	DNA/RNA Synthesis Others	Neurological Disease
PTC258 is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model .

Cat. No.	Product Name

HY-L917

RNA Binding Library

5,000 compounds

RNA is crucial for the regulation of numerous cellular processes and functions. With the in-depth study of disease mechanisms, processes such as RNA expression, splicing, translation, and stability regulation have become new targets for disease intervention. RNA has provided new therapeutic modalities for metabolic diseases, genetic disorders, and cancer patients, resulting in several innovative drugs.

MCE R&D team collected small molecules targeting RNA from the PDB, R-BIND, ROBIN, and internal database as the positive dataset, and non-targeting RNA small molecules from ROBIN as the negative dataset. Based on the GeminiMol pre-trained model, we encoded the molecules and calculated over 1700 molecular descriptors using Mordred as inputs for the model. Subsequently, we employed 13 deep learning models to learn from the data. All of which yielded good training results, with AUROCs greater than 0.75. Ultimately, we selected the Finetune model to screen HY-L901P, which exhibited the best classification performance, achieving an AUROC of 0.82 and a prediction accuracy of 0.76. We then applied filtering based on StaR rules (with at least two of the following properties: cLogP ≥ 1.5, Molar Refractivity ≥ 4, Relative Polar Surface Area ≤ 0.3) to obtain a library containing approximately 5,000 small molecule compounds targeting RNA. This library serves as a valuable tool for screening small molecules that interact with RNA.

Cat. No.	Product Name	Target	Research Area

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	Peptides	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .

HY-P3522

REDV	Integrin	Cancer
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .

Cat. No.	Product Name	Target	Research Area

HY-P990782

Efzofitimod	Aminoacyl-tRNA Synthetase	Inflammation/Immunology
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2360

Hinokiflavone 2 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Selaginellaceae Plants Biflavones Selaginella tamariscina (P. Beauv.) Spring Disease Research Fields Cancer	E1/E2/E3 Enzyme Apoptosis MMP ClpP
Hinokiflavone is a novel modulator of pre-mRNA splicing activity extracted from plants with anti-inflammatory, anti-tumor and antiviral activities. Hinokiflavone is also a potent inhibitor for matrix metalloproteinases (MMPs). Hinokiflavone attenuates the virulence of Methicillin (HY-121544)-resistant staphylococcus aureus by inhibiting caseinolytic protease P (ClpP) with an IC₅₀ value of 34.36 mg/mL. Hinokiflavone induces apoptosis via the reactive oxygen species-mitochondria-mediated apoptotic pathway and inhibits tumor cell migration and invasion. Hinokiflavone is a SUMO protease inhibitor against sentrin-specific protease 1 (SENP1) activity .

HY-N2117

Isoginkgetin 10+ Cited Publications	Structural Classification Flavonoids Ginkgoaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Biflavones Ginkgo biloba Disease Research Fields Cancer	MMP Akt NF-κB Proteasome Apoptosis Autophagy
Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .

HY-N1943

Ailanthone Δ13-Dehydrochaparrinone	Structural Classification Simaroubaceae Ailanthus altissima (Mill.) Swingle Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Androgen Receptor
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC₅₀=69 nM) and constitutively active truncated AR splice variants (AR_1-651 IC₅₀=309 nM).

HY-19828

Herboxidiene GEX1A	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields Biological Pesticide Research Cancer Agricultural Research	DNA/RNA Synthesis
Herboxidiene (GEX1A) is a potent phytotoxic polyketide from Streptomyces sp. A7847 with a diverse range of activities, including herbicidal, anti-cholesterol, anti-tumor effects. Herboxidiene inhibits the pre-mRNA splicing process by binding to spliceosome-associated protein (SAP) 155, a subunit of SF3b, in the splicesome .

HY-139104

Thailanstatin D	Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	DNA/RNA Synthesis Apoptosis
Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis .

HY-139103

Thailanstatin C	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	DNA/RNA Synthesis
Thailanstatin C is a pre-mRNA splicing inhibitor (IC₅₀= 6.84 μM) and antiproliferative agent from Burkholderia thailandensis MSMB43 .

HY-N2117R

Isoginkgetin (Standard)	Structural Classification Flavonoids Ginkgoaceae Source classification Phenols Polyphenols Plants Biflavones Ginkgo biloba	MMP Akt NF-κB Proteasome Apoptosis Autophagy
Isoginkgetin (Standard) is the analytical standard of Isoginkgetin. This product is intended for research and analytical applications. Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .

HY-122970

1,2-Dihydrotanshinone 1,2-Dihydrotanshinquinone	Classification of Application Fields Terpenoids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants Disease Research Fields Inflammation/Immunology	Others
1,2-Dihydrotanshinone (1,2-Dihydrotanshinquinone) is an abietane diterpene. 1,2-Dihydrotanshinone inhibits the formation of the pathogenic complex formed between (CUG)n-RNA and the splicing-factor muscleblind-like 1 (MBNL1). 1,2-Dihydrotanshinone can be used for the research of myotonic dystrophy type 1 .

Cat. No.	Compare	Product Name	Species	Source

HY-P700627

	DBI Protein, Mouse (P. pastoris, His) Dbi; diazepam binding inhibitor; EP; Acbp; ACBD1; endozepine; acyl-CoA-binding protein; diazepam binding inhibitor, splice form 1b	Mouse	P. pastoris
	DBI Protein, with high affinity, binds medium- and long-chain acyl-CoA esters, potentially acting as an intracellular carrier. Moreover, DBI displaces diazepam from the benzodiazepine (BZD) recognition site on the GABA type A receptor, suggesting a neuropeptide role in modulating GABA receptor action. Structurally, as a monomer, DBI underscores the importance of its individual unit in diverse molecular interactions within cellular pathways. DBI Protein, Mouse (P. pastoris, His) is the recombinant mouse-derived DBI protein, expressed by P. pastoris, with N-6*His labeled tag. The total length of DBI Protein, Mouse (P. pastoris, His) is 86 a.a., with molecular weight of 11.9 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-109101S

Risdiplam-d4
Risdiplam-d₄ is deuterium labeled Risdiplam. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1].

HY-109101AS1

Risdiplam-hydroxylate-d3
Risdiplam-hydroxylate-d₃ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-109101AS2

Risdiplam-hydroxylate-d6
Risdiplam-hydroxylate-d₆ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80552

	ATF2 Antibody Activating transcription factor 2 antibody; Activating transcription factor 2 splice variant ATF2 var2 antibody; ATF 2 antibody; Atf-2 antibody; Atf2 antibody; ATF2 protein antibody; ATF2_HUMAN antibody; cAMP Response Element Binding Protein 2 antibody; cAMP response element binding protein CRE BP1 antibody; cAMP response element-binding protein CRE-BP1 antibody; cAMP responsive element binding protein 2, formerly antibody; cAMP-dependent transcription factor ATF-2 antibody; cAMP-responsive element-binding protein 2 antibody; CRE BP1 antibody; CRE-BP antibody; CREB 2 antibody; CREB-2 antibody; CREB2 antibody; CREBP1 antibody; Cyclic AMP dependent transcription factor ATF 2 antibody; Cyclic AMP-dependent transcription factor ATF-2 antibody; Cyclic AMP-responsive element-binding protein 2 antibody; D130078H02Rik antibody; D18875 antibody; HB 16 antibody; HB16 antibody; Histone acetyltransferase ATF2 antibody; MGC105211 antibody; MGC105222 antibody; MGC111558 antibody; MGC142504 antibody; mXBP antibody; MXBP protein antibody; Tg(Gzma-Klra1)7Wum antibody; TREB 7 antibody; TREB7 antibody	WB	Human, Mouse, Rat
	ATF2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 52 kDa, targeting to ATF2. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-112980

Nusinersen 1 Publications Verification		Antisense Oligonucleotides
Nusinersen is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .

HY-112980A

Nusinersen sodium 1 Publications Verification		Antisense Oligonucleotides
Nusinersen sodium is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .

HY-145724A

Drisapersen sodium Kyndrisa sodium; GSK2402968A sodium; PRO051 sodium		Antisense Oligonucleotides
Drisapersen sodium, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.

HY-150237

FITC-labeled Drisapersen sodium		Antisense Oligonucleotides
FITC-labeled Drisapersen (sodium) is Drisapersen labeled with FITC. Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.

HY-148828

LSP-GR3		Antisense Oligonucleotides
LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.

HY-148828A

LSP-GR3 sodium		Antisense Oligonucleotides
LSP-GR3 sodium is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.

HY-145724

Drisapersen Kyndrisa; GSK2402968A; PRO051		Antisense Oligonucleotides
Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.

HY-145976

m7GpppGpG		Cap Analogs Cap 0
m7GpppGpG, an oligonucleotide, is an M ⁷GpppNpG trinucleotide cap analogue. m7GpppGpG prevents premature degradation by 5′-exonucleases and recruits proteins required for pre-mRNA splicing, mRNA transport and initiation of protein biosynthesis .

HY-158828

SSO111 sodium		Antisense Oligonucleotides
SSO111 sodium, a 20mer fully modified antisense oligonucleotide, targets the oncogene?HER2. SSO111 sodium induces exon 15 skipping during splicing, leading to the generation of a novel mRNA transcript that excludes exon 15. SSO111 sodium downregulated HER2 mRNA, which resulted in the inhibition of proliferation and induction of apoptosis in HER2-overexpressing tumor cells.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks